PRNewsWire
13 Feb 2026, 13:00 UTC · 30w ago
Verdict
Headline takes no side. We score CTOR +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Citius Pharmaceuticals has transitioned to a revenue-generating company, reporting $3.9 million in initial sales for LYMPHIR in the first fiscal quarter ended December 31, 2025.
More positive than 91% of claims this week
Management estimates the initial addressable market for LYMPHIR exceeds $400 million and is currently underserved.
So whatDefining a significant target market size provides a baseline for analysts to project future growth and valuation.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 77% of claims this week
The company's late-stage pipeline includes Mino-Lok, which met primary and secondary endpoints in Phase 3 trials, and Halo-Lido, which completed Phase 2b trials.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company successfully launched LYMPHIR, generating initial revenue and tapping into a market estimated to exceed $400 million.
More positive than 99% of ticker scores this week
The company announced its first reported revenue of $3.9 million following the successful launch of LYMPHIR.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
4h ago
−25.6%
Price is moving against the score
$0.8774 vs $1.18 close before publication (Feb 12) · not market-adjusted
CTOR chart →
